Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
- Published In:
- Cancer immunology, immunotherapy : CII, 66(7), 891-901 (2017)
- Authors:
- Lilleby, Wolfgang, Gaudernack, Gustav, Brunsvig, Paal F, Vlatkovic, Ljiljana, Schulz, Melanie, Mills, Kate, Hole, Knut Håkon, Inderberg, Else Marit
- Database ID:
- RPEP-03365
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03365APA
Lilleby, Wolfgang; Gaudernack, Gustav; Brunsvig, Paal F; Vlatkovic, Ljiljana; Schulz, Melanie; Mills, Kate; Hole, Knut Håkon; Inderberg, Else Marit. (2017). Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.. Cancer immunology, immunotherapy : CII, 66(7), 891-901. https://doi.org/10.1007/s00262-017-1994-y
MLA
Lilleby, Wolfgang, et al. "Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.." Cancer immunology, 2017. https://doi.org/10.1007/s00262-017-1994-y
RethinkPeptides
RethinkPeptides Research Database. "Phase I/IIa clinical trial of a novel hTERT peptide vaccine ..." RPEP-03365. Retrieved from https://rethinkpeptides.com/research/lilleby-2017-phase-iiia-clinical-trial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.